134 related articles for article (PubMed ID: 34190510)
1. Evaluation of response to tyrosine kinase inhibitors in renal cell carcinoma patients based on expression of miR-99b, -144, -210, -222, -302а and -377 in tumor tissue.
Vitruk Yu V; Semko SL; Voylenko OA; Pikul MV; Borikun TV; Zadvornyi TV; Yalovenko TM; Stakhovsky EO; Rossylna OV
Exp Oncol; 2021 Jun; 43(2):98-103. PubMed ID: 34190510
[TBL] [Abstract][Full Text] [Related]
2. EXPRESSION OF miRNA AS PROGNOSTIC MARKERS OF RENAL CELL CARCINOMA COURSE.
Vitruk Y; Borikun T; Rossylna O; Zadvornyi T; Semko S; Voylenko O; Stakhovsky O; Shipko A; Stakhovsky E
Exp Oncol; 2022 Aug; 44(2):132-136. PubMed ID: 35964649
[TBL] [Abstract][Full Text] [Related]
3. MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients.
Lukamowicz-Rajska M; Mittmann C; Prummer M; Zhong Q; Bedke J; Hennenlotter J; Stenzl A; Mischo A; Bihr S; Schmidinger M; Vogl U; Blume I; Karlo C; Schraml P; Moch H
Oncotarget; 2016 Nov; 7(48):78433-78447. PubMed ID: 27738339
[TBL] [Abstract][Full Text] [Related]
4. Arterial Spin Labeled Perfusion MRI for the Evaluation of Response to Tyrosine Kinase Inhibition Therapy in Metastatic Renal Cell Carcinoma.
Tsai LL; Bhatt RS; Strob MF; Jegede OA; Sun MRM; Alsop DC; Catalano P; McDermott D; Robson PM; Atkins MB; Pedrosa I
Radiology; 2021 Feb; 298(2):332-340. PubMed ID: 33258745
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population.
Isaacsson Velho P; Nardo M; Souza MCLA; Bonadio RRCC; Marta GN; Muniz DQB; Bastos DA; Dzik C
J Glob Oncol; 2018 Aug; 4():1-10. PubMed ID: 30199304
[TBL] [Abstract][Full Text] [Related]
6. [Pilot Study on MicroRNAs as Biomarkers of Response to Sunitinib Treatment in Patients with Metastatic Renall Cell Carcinoma].
Kováčová J; Juráček J; Poprach A; Büchler T; Kopecký J; Fiala O; Svoboda M; Lojová M; Slabý O
Klin Onkol; 2018; 31(Supplementum1):161-162. PubMed ID: 29808694
[TBL] [Abstract][Full Text] [Related]
7. Candidate MicroRNA Biomarkers of Therapeutic Response to Sunitinib in Metastatic Renal Cell Carcinoma: A Validation Study in Patients with Extremely Good and Poor Response.
Kovacova J; Juracek J; Poprach A; Buchler T; Kopecky J; Fiala O; Svoboda M; Slaby O
Anticancer Res; 2018 May; 38(5):2961-2965. PubMed ID: 29715124
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of copy number variance and sensitivity to common targeted therapy in clear cell renal cell carcinoma: In silico analysis with in vitro validation.
Li Y; Shen Y; Zhu Z; Wen H; Feng C
Cancer Med; 2020 Aug; 9(16):6020-6029. PubMed ID: 32628820
[TBL] [Abstract][Full Text] [Related]
9. miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma.
Sekino Y; Sakamoto N; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
Oncology; 2019; 97(3):164-172. PubMed ID: 31195398
[TBL] [Abstract][Full Text] [Related]
10. Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma.
Annala M; Nappi L; Azad AA; Mo F; Fazli L; Chi KN; Wyatt AW
Clin Genitourin Cancer; 2017 Feb; 15(1):e145-e150. PubMed ID: 27324055
[No Abstract] [Full Text] [Related]
11. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.
Keisner SV; Shah SR
Drugs; 2011 Mar; 71(4):443-54. PubMed ID: 21395357
[TBL] [Abstract][Full Text] [Related]
12. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma.
Prior C; Perez-Gracia JL; Garcia-Donas J; Rodriguez-Antona C; Guruceaga E; Esteban E; Suarez C; Castellano D; del Alba AG; Lozano MD; Carles J; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Gurpide A; Lopez-Picazo JM; Hernandez AG; Mellado B; Martínez E; Moreno F; Font A; Calvo A
PLoS One; 2014; 9(1):e86263. PubMed ID: 24475095
[TBL] [Abstract][Full Text] [Related]
13. Regulation of spindle and kinetochore-associated protein 1 by antitumor miR-10a-5p in renal cell carcinoma.
Arai T; Okato A; Kojima S; Idichi T; Koshizuka K; Kurozumi A; Kato M; Yamazaki K; Ishida Y; Naya Y; Ichikawa T; Seki N
Cancer Sci; 2017 Oct; 108(10):2088-2101. PubMed ID: 28746769
[TBL] [Abstract][Full Text] [Related]
14. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.
Choueiri TK; Fay AP; Gagnon R; Lin Y; Bahamon B; Brown V; Rosenberg JE; Hutson TE; Baker-Neblett KL; Carpenter C; Liu Y; Pandite L; Signoretti S
Clin Cancer Res; 2013 Sep; 19(18):5218-26. PubMed ID: 23881929
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma.
Wood CG; Ferguson JE; Parker JS; Moore DT; Whisenant JG; Maygarden SJ; Wallen EM; Kim WY; Milowsky MI; Beckermann KE; Davis NB; Haake SM; Karam JA; Bortone DS; Vincent BG; Powles T; Rathmell WK
JCI Insight; 2020 Nov; 5(22):. PubMed ID: 33208553
[TBL] [Abstract][Full Text] [Related]
16. MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma.
Kovacova J; Poprach A; Buchler T; Cho WC; Slaby O
Clin Chem Lab Med; 2018 Aug; 56(9):1426-1431. PubMed ID: 29451857
[TBL] [Abstract][Full Text] [Related]
17. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
[TBL] [Abstract][Full Text] [Related]
19. EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation.
Huang H; Gao Y; Liu A; Yang X; Huang F; Xu L; Danfeng X; Chen L
EBioMedicine; 2019 Nov; 49():189-201. PubMed ID: 31669222
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy in Xp11 translocation renal cell carcinoma.
Gomolčáková J; Brezinová B; Dubovan P; Jurišová S; Rejlekova K; Chovanec M; Mardiak J; Mego M
Klin Onkol; 2021; 34(2):137-140. PubMed ID: 33906362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
